Navigation Links
Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
Date:11/25/2009

BASKING RIDGE, N.J., Nov. 25 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David Mazzo, PhD, CEO and President, will be presenting at the Piper Jaffray 21st Annual Health Care Conference at the New York Palace Hotel in New York City. Dr. Mazzo's presentation will be given at 1:10pm (EST) on Tuesday, December 1 and will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. The healthcare industry's leading senior management teams will be presenting at this conference to top institutional investors, equity portfolio managers and research analysts worldwide.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is inten
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
2. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
5. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
6. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
7. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
8. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
9. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Research and Markets has ... Market (Technology, Types, Applications, Services and Geography) - ... their offering. A new report ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020", suggests that the global biosimilars ...
(Date:8/20/2014)... 20, 2014 Research and Markets  has announced ... report to their offering. Global Market ... on Pralmorelin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: Global Coatings for ... This report analyzes the ... US$ Million by the following Product Segments: Active ... The report provides separate comprehensive analytics for the ...
Breaking Medicine Technology:Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2Global Market Report of Pralmorelin 2Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21
... Dec. 29, 2010 Reportlinker.com announces that a ... catalogue: The Market for Pharmaceuticals ... http://www.reportlinker.com/p0203101/The-Market-for-Pharmaceuticals-in-Brazil-Russia-India--China.html Evaluate the ... Brazil, Russia, India and China now and in ...
... Dec. 29, 2010 Centocor Ortho Biotech Inc. announced ... Application (sBLA) with the U.S. Food and Drug Administration ... treatment of moderately to severely active ulcerative colitis (UC) ... to conventional therapy.  REMICADE was designated orphan drug status ...
Cached Medicine Technology:Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 2Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 3Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 4Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 5Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 2Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 3Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 4Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 5Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 6
(Date:8/20/2014)... time to deploy Ebola vaccines is now, Free ... now, according to a commentary being published early online ... . The authors from Yale School of Public Health ... of the current Ebola outbreak represent a public health ... efforts. Several Ebola vaccines have been developed in the ...
(Date:8/20/2014)... Barbara Bronson Gray ... -- Although it,s extremely rare, colds, flu and other ... elevated risk for stroke in children, a new study suggests. ... a stroke in the United States, said Dr. Heather Fullerton, ... and pediatrics at the University of California, San Francisco Benioff ...
(Date:8/20/2014)... Steven Reinberg HealthDay ... The speed at which cancer cells grow may help doctors ... Using this measure, investigators have found that the deadliest ... of older men with a long history of sun exposure. ... the researchers discovered. Rapid cell growth -- called ...
(Date:8/20/2014)... 2014 Park Cities Pet Sitter , ... 4 Pets supply donation drive that benefits the animal shelter ... campaign that coincides with the Humane Society of the United ... through 8th, 2014. , As part of their participation, Park ... monetary donations for the Presents 4 Pets drive from their ...
(Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
Breaking Medicine News(10 mins):Health News:News from Annals of Internal Medicine 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:Salmon forced to 'sprint' less likely to survive migration 2
... of Sciences Leopoldina honored ASU Foundation Professor Bert ... part of the opening ceremonies of the Leopoldina,s ... Hlldobler is highly-regarded, internationally-recognized behavioral scientist ... organization in insects. Ants in particular have served ...
... to perform everyday activities. This is not primarily due to ... was previously believed new research from the University of ... initiate and complete a task towards a specific goal. ... normally results in a degree of paralysis in the lower ...
... A team of researchers from Boston University,s School of ... awarded a five-year, $4.8 million National Institutes of Health ... platform. Based on technologies developed with seed funding ... should be capable of rapidly detecting - at the ...
... high-risk non-melanoma skin carcinomas of the head and neck ... a UNC-led study. Their study is the first to ... simultaneously with radio-and chemotherapy. Scientists with the UNC ... Sept. 26, 2011 online issue of the International ...
... -- The use of long-distance video and data hookups to ... provides the same level of care as having everyone in ... at the Canadian Stroke Congress. The study found that ... Telestroke received an important stroke drug, tPA, at the same ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... linked to the sexually transmitted human papillomavirus (HPV) rose dramatically ... Within a decade, these types of tumors might become the ... the period between 1984 and 1989, just 16.3 percent of ...
Cached Medicine News:Health News:Cothenius Medal awarded to Arizona State University social insect scientist for life's work 2Health News:Cothenius Medal awarded to Arizona State University social insect scientist for life's work 3Health News:Cothenius Medal awarded to Arizona State University social insect scientist for life's work 4Health News:Children with spina bifida need personal 'starter' 2Health News:Researchers from Boston University receive grant to develop improved virus detection system 2Health News:Combination therapy beneficial for head and neck skin carcinomas, UNC study shows 2Health News:Telestroke the next best thing 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 3
Inquire...
Inquire...
Contour I pouches are light as a feather and feature our tapered SoftFlex skin barrier for comformability, flexbility and comfort. All Contour I pouches have ComfortWear panels that keep skin cool an...
Inquire...
Medicine Products: